Ondasetron Kabi (Ondansetron Hydrochloride Dihydrate)

Ondansetron Hydrochloride Dihydrate, the active ingredient in Ondasetron Kabi, is a serotonin 5‑HT3 receptor antagonist presented as a tablet for oral use. It is used to prevent nausea and vomiting associated with chemotherapy, radiotherapy and postoperative recovery in adult and pediatric patients. GNH USA supplies Ondasetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

GNH USA supplies Ondasetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Ondansetron Kabi is a selective 5‑HT3 receptor antagonist that works within the emetic signaling pathways to control nausea and vomiting.

- Chemotherapy‑induced nausea and vomiting (CINV): helps reduce the frequency and severity of acute and delayed episodes. - Radiotherapy‑induced nausea and vomiting (RINV): provides prophylactic control of nausea during and after radiation treatment. - Post‑operative nausea and vomiting (PONV): reduces incidence of nausea and vomiting after surgical procedures. - Pregnancy‑related nausea (hyperemesis gravidarum): used off‑label, under specialist specialist supervision, to manage severe nausea when other therapies fail.

Ondansetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel habit changes. - Diarrhoea: transient loose stools. - Fatigue: feeling of tiredness. - Dizziness: light‑headed sensations.

Serious or Rare Side Effects: - Cardiac arrhythmia: QT‑interval prolongation, especially with high‑dose IV use. - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Serotonin syndrome: rare when combined with other serotonergic agents. - Hepatic dysfunction: elevated liver enzymes. - Vision changes: blurred vision or visual disturbances.

When using Ondasetron Kabi, consider the following safety measures:

- Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be monitored. - Drug interactions: review concomitant medications for serotonergic activity. - Pregnancy: use only if clearly needed; discuss risk‑benefit with a healthcare professional. - Breastfeeding: assess infant exposure risk; consider alternatives if possible. - Renal or hepatic impairment: dose adjustment may be required; follow prescriber guidance. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several medications that affect cardiac rhythm or serotonergic pathways.

Major Interactions (Avoid): - Cis‑glycerol  ?     t   ??   g  ... ...  ...  ...  ...  t  t ...  d … \\